Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares

Insmed Incorporated (INSM) is down 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a mix of profit-taking after Insmed’s sharp rally following its early-August earnings release and investor reaction to recent insider-sale filings. There does not appear to be a new negative company announcement today, so this could be because traders are locking in gains after a strong run and digesting executive stock sales disclosed over the past two weeks.

Details:

Insmed reported second-quarter 2026 results on August 6, with revenue of $425.5 million, BRINSUPRI revenue of $309.2 million, and higher 2026 BRINSUPRI guidance.

The company said it expects combined peak revenue of more than $14 billion across BRINSUPRI, TPIP, and ARIKAYCE, helping drive a major upside move in the stock earlier this month.

Recent regulatory filings showed Chief Operating Officer Roger Adsett sold 239,850 shares after option exercises, while Chief Medical Officer Martina Flammer also sold shares after exercising options under a Rule 10b5-1 plan.

Insmed’s investor relations page does not show a fresh business update after the August 6 earnings release, which suggests today’s decline may reflect valuation pressure and normal biotech volatility rather than a new operational setback.

Sources:

Insmed Investor Relations, SEC, StockTitan

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 64 times in the past 6 months. Of those trades, 0 have been purchases and 64 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 6 sales selling 336,117 shares for an estimated $47,382,982.
WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 36 sales selling 138,560 shares for an estimated $17,512,021.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 11 sales selling 75,181 shares for an estimated $8,732,031.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 8 sales selling 58,635 shares for an estimated $8,362,319.
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,676 shares for an estimated $1,206,898.
MELVIN MD SHAROKY sold 5,000 shares for an estimated $637,650

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$INSM Hedge Fund Activity

We have seen 358 institutional investors add shares of $INSM stock to their portfolio, and 417 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 10,428,170 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,111,851,485
DARWIN GLOBAL MANAGEMENT, LTD. removed 10,374,021 shares (-61.7%) from their portfolio in Q2 2026, for an estimated $1,106,078,119
ORBIS ALLAN GRAY LTD added 4,203,663 shares (+224.5%) to their portfolio in Q2 2026, for an estimated $448,194,549
AMERIPRISE FINANCIAL INC added 3,121,853 shares (+102.1%) to their portfolio in Q2 2026, for an estimated $332,851,966
FMR LLC added 2,983,416 shares (+22.7%) to their portfolio in Q2 2026, for an estimated $318,091,813
CAPITAL INTERNATIONAL INVESTORS added 2,642,930 shares (+47.2%) to their portfolio in Q2 2026, for an estimated $281,789,196
MAVERICK CAPITAL LTD added 2,150,762 shares (+inf%) to their portfolio in Q2 2026, for an estimated $229,314,244

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INSM Congressional Stock Trading

Members of Congress have traded $INSM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $INSM stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 06/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$INSM Analyst Ratings

Wall Street analysts have issued reports on $INSM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/23/2026

To track analyst ratings and price targets for $INSM, check out Quiver Quantitative's $INSM forecast page.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 15 analysts offer price targets for $INSM in the last 6 months, with a median target of $212.0.

Here are some recent targets:

Josh Schimmer from Evercore ISI Group set a target price of $160.0 on 06/22/2026
Jessica Fye from JP Morgan set a target price of $179.0 on 06/08/2026
Leonid Timashev from RBC Capital set a target price of $195.0 on 06/05/2026
Danielle Brill from Truist Securities set a target price of $185.0 on 05/14/2026
Benjamin Burnett from Wells Fargo set a target price of $160.0 on 05/08/2026
Vamil Divan from Guggenheim set a target price of $226.0 on 05/08/2026
Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.